Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan ― The Third Official Report From J-MACS ―

Teruhiko Imamura; Koichiro Kinugawa; Takashi Nishimura; Koichi Toda; Yoshikatsu Saiki; Hiroshi Niinami; Shinichi Nunoda; Goro Matsumiya; Hirokuni Arai; Masanobu Yanase; Norihide Fukushima; Takeshi Nakatani; Akira Shiose; Ikuko Shibasaki; Yasushi Sakata; Masaru Hatano; Minoru Ōno; J-MACS Investigators

doi:10.1253/circj.cj-26-0575

This research is Trending!

Key result

HeartMate 3 and contemporary durable LVAD strategies evaluated for nationwide clinical outcomes in Japan.

Why the study?

Does the introduction of the HeartMate 3 and destination therapy improve clinical outcomes in patients requiring durable LVADs in Japan?

Key Points

Assess nationwide clinical outcomes in Japan following advances in durable left ventricular assist device management and the introduction of the HeartMate 3 system.
Evaluated national registry data from the Japanese Mechanical Circulatory Support (J-MACS) database.
Tracked clinical management trends and outcomes associated with durable left ventricular assist device implantation and destination therapy.
The nationwide experience reflects ongoing shifts in clinical outcomes associated with newer pump technology and destination therapy protocols.

Structured PICO

Does the introduction of the HeartMate 3 and destination therapy improve clinical outcomes in patients requiring durable LVADs in Japan?

P

Population

Patients with durable left ventricular assist device (LVAD) in Japan (from the J-MACS registry)

I

Intervention

HeartMate 3 LVAD and destination therapy

O

Outcome

Clinical outcomes (not specified in the provided text)

Implication

This nationwide registry report aims to clarify the clinical impact of introducing the HeartMate 3 and destination therapy for advanced heart failure patients in Japan.

Abstract

Background: The nationwide impact in Japan of contemporary improvement in the clinical management of durable left ventricular assist device (LVAD), together with the introduction of the HeartMate 3 (Abbott, Pleasanton, CA, USA), on clinical outcomes remains uncertain.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Imamura et al. (2026) studied this question. The HeartMate 3 and contemporary durable left ventricular assist device management strategies were evaluated to determine their nationwide impact on clinical outcomes in Japan.

synapsesocial.com/papers/6ad0e3d6ee876571092a102b https://doi.org/10.1253/circj.cj-26-0575

View Full Paper

Ask AI

Bookmark

Share

Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan ― The Third Official Report From J-MACS ―

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan ― The Third Official Report From J-MACS ―

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading